Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, 34098, Turkey.
Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, 34098, Turkey.
Curr Med Sci. 2021 Dec;41(6):1075-1080. doi: 10.1007/s11596-021-2442-y. Epub 2021 Sep 20.
Corona Virus Disease-2019 (COVID-19) has been among the major infectious events of the century. In today's literature where COVID-19 and host factor effects are frequently examined, we aimed to examine another factor: Circadian Clock Protein PERIOD 3 (PER3). There is a significant correlation between PER3 gene polymorphism and circadian rhythm disturbances and immune system dysregulation.
In our study, we recruited 200 patients diagnosed with COVID-19 in our hospital between April-June 2020, and 100 volunteers without known comorbidities to create a healthy control group. After comparing the initial gene polymorphisms of the patients with healthy controls, three separate clinical subgroups were formed. Gene polymorphism distribution and statistical significance were examined in the formed patient groups.
No significant difference was found between the patient group and the healthy controls (P>0.05, for all). When patients were divided into two separate clinical subgroups as exitus/alive according to their last condition during their 28-day follow-up, the 4R/5R genotype was significantly more common in patients with a mortal course (P=0.007). The PER3 4R/5R genotype was found at a significantly higher rate in the group of patients with the need for intensive care (P=0.034).
The 4R/5R genotype may be associated with the need for intensive care and mortality in COVID-19 patients. These important results will be a guide for future studies.
2019 年冠状病毒病（COVID-19）是本世纪主要传染病之一。在当今经常检查 COVID-19 和宿主因素影响的文献中，我们旨在研究另一个因素：昼夜节律蛋白 PERIOD 3（PER3）。PER3 基因多态性与昼夜节律紊乱和免疫系统失调之间存在显著相关性。
在我们的研究中，我们招募了 200 名 2020 年 4 月至 6 月期间在我院诊断为 COVID-19 的患者，以及 100 名无已知合并症的志愿者作为健康对照组。在比较了患者与健康对照组的初始基因多态性后，形成了三个独立的临床亚组。在形成的患者组中检查了基因多态性分布和统计学意义。
患者组与健康对照组之间未发现显著差异（P>0.05，均）。当根据 28 天随访期间的最后情况将患者分为死亡/存活两个独立的临床亚组时，具有致命病程的患者中 4R/5R 基因型明显更为常见（P=0.007）。需要重症监护的患者中 PER3 4R/5R 基因型的发生率明显更高（P=0.034）。
4R/5R 基因型可能与 COVID-19 患者需要重症监护和死亡率相关。这些重要结果将为未来的研究提供指导。
